drugset / Trial / NCT04010305
Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a two-stage adaptive Phase Ib trial design, that will identify two doses (lowest dose with clinical benefit and highest safe dose) in a first stage and better evaluate safety, tolerability and variability of effect in the second stage.
Timeline
- Start
- 2019-05-22
- Primary completion
- 2019-07-31
- Completion
- 2019-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexmedetomidine | Other / unclassified | 20 ug | Other |
| Subject | Dexmedetomidine | Other / unclassified | 60 ug | Other |
| Subject | Dexmedetomidine | Other / unclassified | 120 ug | Other |
| Subject | Dexmedetomidine | Other / unclassified | 180 ug | Other |